Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Saturday, July 12, 2014 12:00:54 PM
bullish 120% gain or more on margin
perhaps an inverted head and shoulders pattern forming
http://stockcharts.com/school/doku.php?st=head+and+shoulders&id=chart_school:chart_analysis:chart_patterns:head_and_shoulders_bottom_reversal
hidden bullish macd divergence since June
http://www.tradingsetupsreview.com/macd-hidden-divergence-trading-strategy/
$RARE
DD Notes ~ http://www.ddnotesmaker.com/RARE
##### recent news/filings ~ source: finance.yahoo.com
Wed, 09 Jul 2014 10:52:19 GMT ~ Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session
read full: http://finance.yahoo.com/news/ultragenyx-pharmaceutical-slumps-rare-plunges-105219468.html
*********************************************************
Wed, 09 Jul 2014 10:16:06 GMT ~ Ultragenyx Announces Pricing of Public Offering of Common Stock
[at noodls] - NOVATO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/9FFE8CBF956DB796051313BCC01A85BC64120648
*********************************************************
Wed, 09 Jul 2014 05:00:00 GMT ~ Ultragenyx Announces Pricing of Public Offering of Common Stock
[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten ...
read full: http://finance.yahoo.com/news/ultragenyx-announces-pricing-public-offering-050000787.html
*********************************************************
Tue, 08 Jul 2014 18:10:38 GMT ~ Why Ultragenyx Pharmaceutical Inc. Stock Slumped
read full: http://www.fool.com/investing/general/2014/07/08/why-ultragenyx-pharmaceutical-inc-stock-slumped.aspx?source=eogyholnk0000001
*********************************************************
Mon, 07 Jul 2014 20:41:47 GMT ~ Ultragenyx Announces Proposed Public Offering of Common Stock
[at noodls] - NOVATO, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/C0A7B5AFC8509CEBEF230D67C95F9CEC8E0806B3
*********************************************************
##### chart ~ source: stockcharts.com
##### chart ~ source: eoddata.com
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:
##### extra dd links
Latest filings: http://www.otcmarkets.com/stock/RARE/filings
Latest financials: http://www.otcmarkets.com/stock/RARE/financials
Latest news: http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines
Major holdings: http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=RARE
RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
DTCC: http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0
Short Sales: http://www.otcmarkets.com/stock/RARE/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/RARE/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/RARE/research
Historical Prices: http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=RARE+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=RARE+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=RARE
Balance Sheet: http://finance.yahoo.com/q/bs?s=RARE
Cash Flow: http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/RARE
Bloomberg: http://www.bloomberg.com/quote/RARE:US
Morningstar: http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE
Barchart: http://www.barchart.com/quotes/stocks/RARE
OTC Short Report: http://otcshortreport.com/index.php?index=RARE
Investopedia: http://www.investopedia.com/markets/stocks/RARE/?wa=0
http://www.pennystocktweets.com/stocks/profile/RARE
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/RARE
a11k
Recent RARE News
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/19/2024 08:30:00 PM
- Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 • GlobeNewswire Inc. • 04/15/2024 11:00:00 AM
- Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome • GlobeNewswire Inc. • 04/12/2024 08:22:53 PM
- Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting • GlobeNewswire Inc. • 04/12/2024 12:00:00 PM
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/22/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:23:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:22:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:17:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:15:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:13:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:10:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:08:18 AM
- Ultragenyx to Participate at Investor Conferences in March • GlobeNewswire Inc. • 02/27/2024 09:30:00 PM
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/23/2024 09:05:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/21/2024 10:03:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:04:29 PM
- Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 02/15/2024 09:01:00 PM
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 02/08/2024 09:00:00 PM
- Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome • GlobeNewswire Inc. • 02/05/2024 09:05:00 PM
- Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease • GlobeNewswire Inc. • 01/25/2024 09:05:00 PM
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/19/2024 09:00:00 PM
- Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments • GlobeNewswire Inc. • 01/08/2024 12:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:03:45 AM
- Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones • GlobeNewswire Inc. • 01/07/2024 04:00:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM